SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial
A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.
